Raymond James & Associates Has $4.99 Million Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Raymond James & Associates lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 8.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,915 shares of the medical research company’s stock after purchasing an additional 1,179 shares during the period. Raymond James & Associates owned 0.05% of Bio-Rad Laboratories worth $4,990,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. First Eagle Investment Management LLC lifted its stake in shares of Bio-Rad Laboratories by 32,296.9% in the 2nd quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock valued at $173,773,000 after purchasing an additional 634,311 shares during the last quarter. Swedbank AB acquired a new stake in shares of Bio-Rad Laboratories in the 1st quarter valued at $1,824,000. DAVENPORT & Co LLC acquired a new stake in shares of Bio-Rad Laboratories in the 1st quarter valued at $15,340,000. Gabelli Funds LLC lifted its stake in shares of Bio-Rad Laboratories by 16.8% in the 1st quarter. Gabelli Funds LLC now owns 41,800 shares of the medical research company’s stock valued at $14,457,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Qsemble Capital Management LP acquired a new position in Bio-Rad Laboratories during the 1st quarter worth $567,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Insider Activity at Bio-Rad Laboratories

In related news, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the sale, the chief operating officer now owns 7,559 shares of the company’s stock, valued at $2,494,016.46. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Andrew J. Last sold 3,000 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the transaction, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BIO has been the subject of a number of research analyst reports. Citigroup boosted their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price for the company. Royal Bank of Canada boosted their target price on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $391.80.

Bio-Rad Laboratories Stock Performance

NYSE:BIO opened at $368.42 on Friday. The firm’s 50-day moving average is $333.99 and its 200-day moving average is $308.47. Bio-Rad Laboratories, Inc. has a 52-week low of $262.12 and a 52-week high of $372.27. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 6.28. The company has a market cap of $10.27 billion, a price-to-earnings ratio of -13.48 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.73. The business had revenue of $649.70 million for the quarter, compared to analysts’ expectations of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.66%. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.33 earnings per share. Equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.45 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.